| Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR–MET interaction and activation of MET signaling in colon cancer cells T Troiani, E Martinelli, S Napolitano, D Vitagliano, LP Ciuffreda, ... Clinical cancer research 19 (24), 6751-6765, 2013 | 157 | 2013 |
| Targeting EGFR in pancreatic cancer treatment T Troiani, E Martinelli, A Capasso, F Morgillo, M Orditura, F De Vita, ... Current drug targets 13 (6), 802-810, 2012 | 152 | 2012 |
| Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts A Capasso, J Lang, TM Pitts, KR Jordan, CH Lieu, SL Davis, JR Diamond, ... Journal for immunotherapy of cancer 7, 1-16, 2019 | 137 | 2019 |
| Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition T Troiani, S Napolitano, D Vitagliano, F Morgillo, A Capasso, V Sforza, ... Clinical cancer research 20 (14), 3775-3786, 2014 | 118 | 2014 |
| Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human … E Martinelli, T Troiani, E D'Aiuto, F Morgillo, D Vitagliano, A Capasso, ... International journal of cancer 133 (9), 2089-2101, 2013 | 108 | 2013 |
| The changing landscape of phase I trials in oncology KM Wong, A Capasso, SG Eckhardt Nature reviews Clinical oncology 13 (2), 106-117, 2016 | 107 | 2016 |
| Recent trends in the age at diagnosis of colorectal cancer in the US National Cancer Data Base, 2004‐2015 J Virostko, A Capasso, TE Yankeelov, B Goodgame Cancer 125 (21), 3828-3835, 2019 | 99 | 2019 |
| The link between kidney disease and cancer: complications and treatment J Malyszko, P Tesarova, G Capasso, A Capasso The Lancet 396 (10246), 277-287, 2020 | 90 | 2020 |
| Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells E Martinelli, T Troiani, F Morgillo, G Rodolico, D Vitagliano, MP Morelli, ... Clinical Cancer Research 16 (20), 4990-5001, 2010 | 89 | 2010 |
| A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial SI Ou, M Koczywas, S Ulahannan, P Janne, J Pacheco, H Burris, ... Journal of Thoracic Oncology 15 (2), S15-S16, 2020 | 61 | 2020 |
| Summary of the International Conference on Onco-Nephrology: an emerging field in medicine A Capasso, A Benigni, U Capitanio, FR Danesh, V Di Marzo, L Gesualdo, ... Kidney international 96 (3), 555-567, 2019 | 60 | 2019 |
| Rapamycin-induced phosphaturia DS Kempe, M Dërmaku-Sopjani, H Fröhlich, M Sopjani, A Umbach, ... Nephrology Dialysis Transplantation 25 (9), 2938-2944, 2010 | 60 | 2010 |
| A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer JR Diamond, SG Eckhardt, TM Pitts, A van Bokhoven, D Aisner, ... Breast Cancer Research 20, 1-10, 2018 | 52 | 2018 |
| Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells T Troiani, L Vecchione, E Martinelli, A Capasso, S Costantino, ... British journal of cancer 106 (10), 1648-1659, 2012 | 51 | 2012 |
| Development of an adrenocortical cancer humanized mouse model to characterize anti-PD1 effects on tumor microenvironment J Lang, A Capasso, KR Jordan, JD French, A Kar, SM Bagby, J Barbee, ... The Journal of Clinical Endocrinology & Metabolism 105 (1), 26-42, 2020 | 45 | 2020 |
| Cabozantinib exhibits potent antitumor activity in colorectal cancer patient-derived tumor xenograft models via autophagy and signaling mechanisms AJ Scott, JJ Arcaroli, SM Bagby, R Yahn, KM Huber, NJ Serkova, ... Molecular cancer therapeutics 17 (10), 2112-2122, 2018 | 37 | 2018 |
| The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance KS Quackenbush, S Bagby, WM Tai, WA Messersmith, A Schreiber, ... Oncotarget 7 (19), 28273, 2016 | 37 | 2016 |
| Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment E Martinelli, V Sforza, C Cardone, A Capasso, A Nappi, G Martini, ... ESMO open 2 (3), e000177, 2017 | 35 | 2017 |
| BRAF fusions identified in melanomas have variable treatment responses and phenotypes JA Turner, JGT Bemis, SM Bagby, A Capasso, BW Yacob, TS Chimed, ... Oncogene 38 (8), 1296-1308, 2019 | 33 | 2019 |
| Genomic and proteomic approaches to renal cell carcinoma M Zacchia, A Vilasi, A Capasso, F Morelli, F De Vita, G Capasso Journal of Nephrology 24 (2), 155, 2011 | 31 | 2011 |
Todd M PittsUniversity of Colorado Anschutz Medical CampusVerified email at ucdenver.edu
